• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
CommentaryHealth

I’m an obesity medicine doctor and I’ve been on weight-loss drugs like Ozempic for a decade. Here’s why I think they aren’t a fad

By
Angela Fitch
Angela Fitch
Down Arrow Button Icon
By
Angela Fitch
Angela Fitch
Down Arrow Button Icon
July 30, 2024, 12:23 PM ET
Dr. Angela Fitch is cofounder and chief medical officer of knownwell.
Angela Fitch. cofounder and chief medical officer of knownwell.
Angela Fitch has seen results with GLP-1s like Ozempic and Wegovy.courtesy of knownwell

For as long as I can remember, obesity has affected me and my family. From my father to my brother and even five generations before that, the disease was in our DNA—starting in childhood for some and later in life for others.

Obesity met me in med school, and not just on the pages of my textbooks. My routine was flipped upside down, and I was all of a sudden struggling with my weight and overall health. Pulling all-nighters and on many days getting my sustenance from the hospital vending machine, I went from being somebody who never gave much thought to what food I was putting into my body to someone who quickly noticed my serving sizes were getting larger and larger. Dealing with the stress of residency, and shortly thereafter the stresses of pregnancy, like many people I found myself eating the standard American diet and gaining weight. The reality was, I was predisposed to this disease—I’d just made it that far without experiencing it first-hand. Once I experienced it, it felt nearly impossible to manage.

I knew I wasn’t alone, but that didn’t make it any easier. And surprisingly, despite being on the path to becoming a doctor myself, I found it difficult to get the care I needed. Globally, one in eight people are living with obesity, yet despite it affecting such a large portion of the population, it’s historically been associated with shame and judgment—with only one’s lifestyle choices to blame. It wasn’t until 2013 when the American Medical Association (AMA) recognized obesity as a disease that required treatment and prevention. Ironically, I was board certified in obesity medicine one year prior, already on a mission to close the gaping holes in care for people like myself.

At 200 pounds, I was embarrassed to admit I needed more than just a change in eating habits. Like many of my patients, I was exercising (Peloton and lifting weights twice a week with my trainer) and eating a healthy unprocessed diet but would only see 5 pounds of weight loss and then stall. At the time I was working on studies supporting the use of GLP-1s—drugs including Ozempic, Saxenda, and Wegovy that help control blood sugar by boosting insulin, curbing appetite, and slowing digestion—and prescribing and seeing results through my patients. Yet, I still thought I was supposed to lose the weight on my own. I had developed high blood pressure and mild sleep apnea, and I was headed down a medical comorbidity path I did not want to follow.

I wasn’t practicing what I was preaching until 2014, when Saxenda was approved by the FDA for weight management. In just 12 months of being on the medication, I’d lost 20% of my weight, what medical nerds like me would call a “high responder.” I continued the medication for another three years, despite my health plan not covering it—a conversation for a different time—because it was working, and the weight wasn’t coming back.

Work moved me to Boston, leaving me without a primary care physician and a prescription to GLP-1s. Already at a healthy weight, I decided to give it a try on my own. I was living the lifestyle I’d been recommending for years, and for the first six months, it worked. Eventually, like the randomized controlled trials show, I slowly gained back 20 pounds and realized working out and eating well wasn’t enough for my body—and I needed to accept that.

Nearly a decade later, having taken a variety of GLP-1s from Saxenda to Ozempic to Wegovy, which I take now, I’ve learned a few things that should have been taught in med school.

Most diseases can’t be treated solely with lifestyle intervention, and obesity is no exception. Medication usage isn’t one size fits all. Some people may find success in temporary usage while others, like me, may need to take it long term. Obesity is a domino for other health conditions—from sleep apnea to cardiovascular issues to poor mental health. For me, perhaps the biggest lesson I’ve learned through my experience is that there isn’t enough obesity care without the bias, shame, and blame.

I cofounded knownwell, a metabolic health company focusing on comprehensive obesity and primary care, to give people like myself a place to feel seen and heard. Even I, an obesity medicine specialist, needed a village—top doctors, dietitians, trainers, and more—to get me to where I am on my health journey today. I hope to be part of that village for others.

Although it feels like GLP-1s like Ozempic and Wegovy are brand new because everybody is talking about them, the reality is, they’ve been a science-backed solution for people living with obesity for over a decade. This isn’t just a fad, and it’s not an easy fix—it’s a step in the right direction toward bridging the gap in chronic care for the disease of obesity.

People may judge those of us who choose to manage our obesity with comprehensive care by adding medication and surgery instead of relying solely on “diet culture,” but having taken medication myself for nearly 10 years, I can tell you, I’ve never been healthier. I’d much rather stick with weekly injections alongside a balanced diet and exercise plan, which supports a longer, healthier life, than risk gaining weight back and facing the complications that go with it. 

There is no “easy way” to lose weight. Weight loss isn’t a normal function of the human body, and many of us are genetically predisposed to abnormal weight gain in our current environment. Yes, the environment we live in needs to change, too, but right now, we have to live the best we can with the tools we have at our disposal—one tool being drugs like Ozempic.

More reading:

  • Weaning off Ozempic slowly instead of quitting abruptly can help prevent patients from regaining weight, study says
  • How drugs like Ozempic and Wegovy work for weight loss: ‘Food tastes good, but I don’t want it’
  • Weight-loss-aiding drugs Ozempic and Wegovy are dampening food sales, top Walmart exec says
  • The 5 biggest weight loss myths that ‘need to die,’ according to an obesity doctor

The opinions expressed in Fortune.com commentary pieces are solely the views of their authors and do not necessarily reflect the opinions and beliefs of Fortune.

Fortune Brainstorm AI returns to San Francisco Dec. 8–9 to convene the smartest people we know—technologists, entrepreneurs, Fortune Global 500 executives, investors, policymakers, and the brilliant minds in between—to explore and interrogate the most pressing questions about AI at another pivotal moment. Register here.
About the Author
By Angela Fitch
See full bioRight Arrow Button Icon

Latest in Commentary

Google.org
CommentaryTech
Nonprofits are solving 21st century problems—they need 21st century tech
By Maggie Johnson and Shannon FarleyDecember 8, 2025
4 hours ago
Will Dunham is President and Chief Executive Officer of the American Investment Council
CommentaryRetirement
Private equity is being villainized in the retirement debate — even as it provides diversification and outperforms public markets long-term
By Will DunhamDecember 8, 2025
4 hours ago
Justin Hotard, CEO of Nokia
CommentaryGen Z
Nokia CEO: The workforce is becoming AI-native. Leadership has to evolve
By Justin HotardDecember 8, 2025
7 hours ago
Alex Amouyel is the President and CEO of Newman’s Own Foundation
Commentaryphilanthropy
Following in Paul Newman and Yvon Chouinard’s footsteps: There are more ways for leaders to give it away in ‘the Great Boomer Fire Sale’ than ever
By Alex AmouyelDecember 7, 2025
1 day ago
Amit Walia
CommentaryM&A
Why the timing was right for Salesforce’s $8 billion acquisition of Informatica — and for the opportunities ahead
By Amit WaliaDecember 6, 2025
2 days ago
Steve Milton is the CEO of Chain, a culinary-led pop-culture experience company founded by B.J. Novak and backed by Studio Ramsay Global.
CommentaryFood and drink
Affordability isn’t enough. Fast-casual restaurants need a fandom-first approach
By Steve MiltonDecember 5, 2025
3 days ago

Most Popular

placeholder alt text
Real Estate
The 'Great Housing Reset' is coming: Income growth will outpace home-price growth in 2026, Redfin forecasts
By Nino PaoliDecember 6, 2025
2 days ago
placeholder alt text
Politics
Supreme Court to reconsider a 90-year-old unanimous ruling that limits presidential power on removing heads of independent agencies
By Mark Sherman and The Associated PressDecember 7, 2025
1 day ago
placeholder alt text
AI
Nvidia CEO says data centers take about 3 years to construct in the U.S., while in China 'they can build a hospital in a weekend'
By Nino PaoliDecember 6, 2025
2 days ago
placeholder alt text
Economy
The most likely solution to the U.S. debt crisis is severe austerity triggered by a fiscal calamity, former White House economic adviser says
By Jason MaDecember 6, 2025
2 days ago
placeholder alt text
Uncategorized
Transforming customer support through intelligent AI operations
By Lauren ChomiukNovember 26, 2025
12 days ago
placeholder alt text
Economy
JPMorgan CEO Jamie Dimon says Europe has a 'real problem’
By Katherine Chiglinsky and BloombergDecember 6, 2025
2 days ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.